Compare GLSI & RNGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLSI | RNGT |
|---|---|---|
| Founded | 2006 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.6M | 315.5M |
| IPO Year | 2020 | N/A |
| Metric | GLSI | RNGT |
|---|---|---|
| Price | $12.98 | $10.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 195.1K | 18.6K |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.78 | $9.90 |
| 52 Week High | $34.10 | $10.16 |
| Indicator | GLSI | RNGT |
|---|---|---|
| Relative Strength Index (RSI) | 28.27 | 57.36 |
| Support Level | $8.19 | $9.95 |
| Resistance Level | $14.19 | $10.13 |
| Average True Range (ATR) | 1.97 | 0.02 |
| MACD | -0.56 | 0.00 |
| Stochastic Oscillator | 5.98 | 55.56 |
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Range Capital Acquisition Corp II is a blank check company.